eligibility_summary
Include: Adults ≥18 with confirmed CLL/SLL per 2018 iwCLL who need treatment, ECOG ≤2, adequate organ (CrCl ≥30, AST/ALT ≤2.5×ULN, bilirubin <3×ULN) and marrow (ANC ≥1.0k, Hgb ≥7, platelets ≥75k or ≥30k if disease) function, consent, contraception. Exclude: prior CLL therapy, other active cancer, immunosuppression, AIHA/ITP, PLL/Richter, bleeding/warfarin, serious infection, PML, major CV/CNS disease, recent surgery, malabsorption, HIV, active HBV/HCV, CYP3A drugs/grapefruit, cancer steroids, obinutuzumab allergy, live vaccine ≤28d, pregnancy/breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II, open-label CLL/SLL trial evaluating frontline zanubrutinib + venetoclax with response-adapted obinutuzumab for MRD-positive patients. Drugs/mechanisms (type): - Zanubrutinib: small-molecule covalent Brutons tyrosine kinase (BTK) inhibitor, blocks B‑cell receptor (BCR) signaling to suppress malignant B‑cell proliferation/survival. - Venetoclax: small-molecule BH3‑mimetic BCL‑2 inhibitor, restores intrinsic (mitochondrial) apoptosis in CLL cells. - Obinutuzumab: glycoengineered type II anti‑CD20 monoclonal antibody, induces direct cell death and ADCC/CDC of CD20+ B cells. Targets: BTK/BCR signaling pathway, anti-apoptotic BCL‑2 pathway, and CD20+ malignant B lymphocytes, aiming to eradicate MRD while limiting anti‑CD20 exposure.